Medivolve Inc.
MEDVFOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$2702
P/E Ratio—
52W High$0.002
52W Low$0.0001
Medivolve Inc. (MEDVF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MEDVF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: May 31, 2024EPS Actual
-$0.03
Revenue
$0.00B
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 31, 2024
After Market Close
MEDVF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2025 | May 30, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 5, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Feb 13, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Dec 17, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Sep 27, 2024 | — | — | — | — | — | — |
| — Q2 FY2024 | May 31, 2024 | — | -$0.03 | — | $0.00B | — | — |
| — Q2 FY2024 | Apr 1, 2024 | — | -$0.23 | — | $0.00B | — | — |
| — Q4 FY2023 | Nov 14, 2023 | — | -$0.10 | — | $0.00B | — | — |
Q2 FY2025
May 30, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 5, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 13, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 17, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Sep 27, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 31, 2024
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
Apr 1, 2024
EPS Actual
-$0.23
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2023
Nov 14, 2023
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $2.09 | $2.09 | $2.09 | 1 |
| Q2 FY2024 | $1.83 | $1.83 | $1.83 | 1 |
| Q1 FY2024 | $2.14 | $2.14 | $2.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2024 | May 31, 2024 | — | $0.01 | $0.01 | +40.00% |
| — Q2 FY2024 | Apr 1, 2024 | — | $0.01 | $0.01 | +0.00% |
| — Q4 FY2023 | Nov 14, 2023 | — | $0.03 | $0.03 | +0.00% |
| — Q3 FY2023 | Aug 14, 2023 | — | $0.05 | $0.04 | -9.46% |
| — Q2 FY2023 | May 15, 2023 | — | $0.06 | $0.06 | +0.00% |
| — Q1 FY2023 | Mar 29, 2023 | — | $0.07 | $0.06 | -21.78% |
| — Q4 FY2022 | Nov 14, 2022 | — | $0.21 | $0.00 | -99.55% |
Q2 FY2024+40.00%
Report Date
May 31, 2024
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q2 FY2024+0.00%
Report Date
Apr 1, 2024
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q4 FY2023+0.00%
Report Date
Nov 14, 2023
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.03
Q3 FY2023-9.46%
Report Date
Aug 14, 2023
EPS Beat/Miss
—
Price Before
$0.05
Price After
$0.04
Q2 FY2023+0.00%
Report Date
May 15, 2023
EPS Beat/Miss
—
Price Before
$0.06
Price After
$0.06
Q1 FY2023-21.78%
Report Date
Mar 29, 2023
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.06
Q4 FY2022-99.55%
Report Date
Nov 14, 2022
EPS Beat/Miss
—
Price Before
$0.21
Price After
$0.00
Beat Rate0 / 7 quarters
Largest Move-99.55% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MEDVF ends December
Medivolve Inc. (MEDVF) most recently reported earnings on May 31, 2024 for Q2 FY2024, posting EPS of $-0.03 (in line with the analyst consensus of —). The next MEDVF earnings date is expected around September 1, 2026.
Each quarter, investors track MEDVF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MEDVF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MEDVF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MEDVF earnings · 4 questionsMedivolve Inc.'s next earnings report is expected around September 1, 2026. MEDVF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MEDVF historically reports after market close (AMC).
MEDVF earnings datewhen is MEDVF earningsMEDVF next earnings datewhen does MEDVF report earningsMEDVF earnings calendar
▸ Source: FMP · Medivolve Inc. SEC filings · US GAAP · Medivolve Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026